DIM-C-pPhCO2Me
Based on 1 publication(s) in Google Scholar
DIM-C-pPhCO2Me is a nuclear receptor 4A1 (NR4A1) antagonist. DIM-C-pPhCO2Me induces Apoptosis. DIM-C-pPhCO2Me decreases PAX3-FOXO1A, N-Myc, Rassf4, MyoD1, Grem1, and DAPK1 proteins. DIM-C-pPhCO2Me decreases expression of TXNDC5 and IDH1, induces markers of ER stress (CHOP, ATF4 and p-PERK). DIM-C-pPhCO2Me inhibits renal cell carcinoma, breast cancer. DIM-C-pPhCO2Me can also be used in rhabdomyosarcoma research.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté : 99.29%
- CAS No.: 151358-48-4
- Formule: C25H20N2O2
- Masse moléculaire:380.44
-
Stockage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Protocole
- Pureté et documentation
- Références
-
Help & FAQs
-
HY-112055
DIM-C-pPhOHNR4A1 Antagonist -
HY-111492
DIM-C-pPhOCH3Nur77 Agonist -
HY-19808
C-DIM12Nurr1 Activator -
HY-B1322
Amodiaquine dihydrochloride dihydrateAntimalarial Agent -
HY-N2148
Cytosporone BNur77/NR4A1 Agonist -
HY-100875
BisantreneAntitumor Agent -
HY-B1322R
Amodiaquine dihydrochloride dihydrate (Standard)Antimalarial Agent
Publications Citing Use of MedChemExpress (MCE) DIM-C-pPhCO2Me
MoreVoir tous les produits spécifiques à Isoform Nuclear Hormone Receptor 4A/NR4A
More
Activité biologique
Description
|
Nur77/NR4A1 |
IDH1 |
In Vitro
DIM-C-pPhCO2Me (0-20 μM, 24 h) inhibits growth and induces apoptosis in ACHN and 786-O cells[1].
DIM-C-pPhCO2Me (7.5-20 μM, 24 h) significantly inhibits growth of MCF-7, MDA-MB-231 cells[2].
DIM-C-pPhCO2Me (24 h) induces IL24 gene expression in Rh30 cells[3].
DIM-C-pPhCO2Me (24 h) decreases expression of PAX3-FOXO1A protein accompanied by downregulation of N-Myc, Rassf4, MyoD1, Grem1, and DAPK1 proteins in Rh30 cells[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:RCC cell lines (ACHN and 786-O)
-
Concentration:7.5, 15, 20 µM
-
Incubation Time:24 h
-
Result:Decreased cell proliferation.
Showed IC50 value of 11.7 μM in ACHN cells.
Showed IC50 value of 13.4 μM in 786-O cells.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Male mice with E. coli pneumonia[5]
-
Dosage:2 mg/kg, single dose
-
Administration:intratracheally, 30 min before E. coli infection
-
Result:Showed an obvious augmented phagocytic activity.
Reduced the mortality in mice undergoing E. coli pneumonia (36.6% vs. 75%).
Chemical Information
-
CAS No. 151358-48-4
-
Appearance Solid
-
Masse moléculaire 380.44
-
Formule C25H20N2O2
-
Color Light yellow to yellow
-
SMILES
COC(C1=CC=C(C(C2=CNC3=C2C=CC=C3)C4=CNC5=C4C=CC=C5)C=C1)=O
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
J Biol Chem
PPARγ and C/EBPα enable adipocyte differentiation upon inhibition of histone methyltransferase PRC2 in malignant tumors. [Abstract]2024 Oct;300(10):107765. PMID: 39276936
Solvant et solubilité
In Vitro:
DMSO : ≥ 125 mg/mL (328.57 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
In Vivo:
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL (5.47 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.08 mg/mL (5.47 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureté et documentation
-
Fiche technique (283 KB)
-
SDS (254 KB)
- English - EN (254 KB)
- Français - FR (254 KB)
- Deutsch - DE (254 KB)
- Norwegian - NO (254 KB)
- Español - ES (254 KB)
- Swedish - SV (254 KB)
- Italian - IT (254 KB)
- Korean - KR (254 KB)
- Portuguese - PT (254 KB)
-
Instruction de manipulation (2659 KB)
Références
[1]. Hedrick E, et al. Nuclear Receptor 4A1 (NR4A1) as a Drug Target for Renal Cell Adenocarcinoma. PLoS One. 2015 Jun 2;10(6):e0128308. [Content Brief]
[2]. Hedrick E, et al. Nuclear receptor 4A1 as a drug target for breast cancer chemotherapy. Endocr Relat Cancer. 2015 Oct;22(5):831-40. [Content Brief]
[3]. Lacey A, et al. Interleukin-24 (IL24) Is Suppressed by PAX3-FOXO1 and Is a Novel Therapy for Rhabdomyosarcoma. Mol Cancer Ther. 2018 Dec;17(12):2756-2766. [Content Brief]
[4]. Lacey A, et al. PAX3-FOXO1A Expression in Rhabdomyosarcoma Is Driven by the Targetable Nuclear Receptor NR4A1. Cancer Res. 2017 Feb 1;77(3):732-741. [Content Brief]
[5]. Cui P, et al. Deficiency of the Transcription Factor NR4A1 Enhances Bacterial Clearance and Prevents Lung Injury During Escherichia Coli Pneumonia. Shock. 2019 Jun;51(6):787-794. [Content Brief]
Hot Topics
-
All
-
Topics
-
Most Recent
-
Oldest
-
Topics ER Stress: From Cellular Surveillance to Disease Pathogenesis
Proteostasis is the basis of cell survival.
2025-10-13
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.6285 mL | 13.1427 mL | 26.2854 mL | 65.7134 mL |
| 5 mM | 0.5257 mL | 2.6285 mL | 5.2571 mL | 13.1427 mL | |
| 10 mM | 0.2629 mL | 1.3143 mL | 2.6285 mL | 6.5713 mL | |
| 15 mM | 0.1752 mL | 0.8762 mL | 1.7524 mL | 4.3809 mL | |
| 20 mM | 0.1314 mL | 0.6571 mL | 1.3143 mL | 3.2857 mL | |
| 25 mM | 0.1051 mL | 0.5257 mL | 1.0514 mL | 2.6285 mL | |
| 30 mM | 0.0876 mL | 0.4381 mL | 0.8762 mL | 2.1904 mL | |
| 40 mM | 0.0657 mL | 0.3286 mL | 0.6571 mL | 1.6428 mL | |
| 50 mM | 0.0526 mL | 0.2629 mL | 0.5257 mL | 1.3143 mL | |
| 60 mM | 0.0438 mL | 0.2190 mL | 0.4381 mL | 1.0952 mL | |
| 80 mM | 0.0329 mL | 0.1643 mL | 0.3286 mL | 0.8214 mL | |
| 100 mM | 0.0263 mL | 0.1314 mL | 0.2629 mL | 0.6571 mL |
DIM-C-pPhCO2Me Related Classifications
HY-112056 Related Classifications
Powered by Bioz
Keywords
- DIM-C-pPhCO2Me
- 151358-48-4
- Nuclear Hormone Receptor 4A/NR4A
- Apoptosis
- DAPK
- Isocitrate Dehydrogenase (IDH)
- PERK
- Nuclear Hormone Receptor 4A
- Nerve Growth Factor IB-like Receptor
- Death associated protein kinase
- Protein kinase R-like endoplasmic reticulum kinase
- PKR-like endoplasmic reticulum kinase
- Rh30
- ACHN
- 786-O
- renal cell carcinoma
- breast cancer
- mice
- anti-tumor.
- Inhibitor
- inhibitor
- inhibit